Unknown

Dataset Information

0

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.


ABSTRACT: OBJECTIVE:Preclinical data suggest elesclomol increases oxidative stress and enhances sensitivity to cytotoxic agents. The objective of this prospective multicenter phase 2 trial was to estimate the activity of IV elesclomol plus weekly paclitaxel in patients with platinum-resistant recurrent ovarian, tubal or peritoneal cancer through the frequency of objective tumor responses (ORR). METHODS:Patients with measurable disease, acceptable organ function, performance status???2, and one prior platinum containing regimen were eligible. A two-stage design was utilized with a target sample size of 22 and 30 subjects, respectively. Prior Gynecologic Oncology Group studies within the same population involving single agent taxanes showed an ORR of approximately (20%) and served as a historical control for direct comparison. The present study was designed to determine if the regimen had an ORR of ?40% with 90% power. RESULTS:Fifty-eight patients were enrolled, of whom 2 received no study treatment and were inevaluable. The median number of cycles was 3 (268 total cycles, range 1-18). The number of patients responding was 11 (19.6%; 90% CI 11.4% to 30.4%) with one complete response. The median progression-free survival and overall survival was 3.6?months and 13.3?months, respectively. The median ORR duration was 9.2?months. Percentages of subjects with grade 3 toxicity included: Neutropenia 9%; anemia 5%; metabolic 5%; nausea 4%; infection 4%; neurologic (mostly neuropathy) 4%; and vascular (mostly thromboembolism) 4%. There were no grade 4 toxicities reported. CONCLUSIONS:This combination was well tolerated but is unworthy of further investigation based on the proportion responding [ClinicalTrials.gov Identifier: NCT00888615].

SUBMITTER: Monk BJ 

PROVIDER: S-EPMC6392076 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.

Monk Bradley J BJ   Kauderer James T JT   Moxley Katherine M KM   Bonebrake Albert J AJ   Dewdney Summer B SB   Secord Angeles Alvarez AA   Ueland Frederick R FR   Johnston Carolyn M CM   Aghajanian Carol C  

Gynecologic oncology 20181008 3


<h4>Objective</h4>Preclinical data suggest elesclomol increases oxidative stress and enhances sensitivity to cytotoxic agents. The objective of this prospective multicenter phase 2 trial was to estimate the activity of IV elesclomol plus weekly paclitaxel in patients with platinum-resistant recurrent ovarian, tubal or peritoneal cancer through the frequency of objective tumor responses (ORR).<h4>Methods</h4>Patients with measurable disease, acceptable organ function, performance status ≤ 2, and  ...[more]

Similar Datasets

| S-EPMC6542283 | biostudies-literature
| S-EPMC5570471 | biostudies-literature
| S-EPMC4698796 | biostudies-literature
| S-EPMC3201726 | biostudies-other
| S-EPMC8853032 | biostudies-literature
| S-EPMC10529107 | biostudies-literature
| S-EPMC4677992 | biostudies-literature
| S-EPMC7930451 | biostudies-literature
| S-EPMC3081997 | biostudies-literature
| S-EPMC7403557 | biostudies-literature